Literature DB >> 23529183

C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling.

Sebastiano Sciarretta1, Simona Marchitti, Franca Bianchi, Amie Moyes, Emanuele Barbato, Sara Di Castro, Rosita Stanzione, Maria Cotugno, Lorenzo Castello, Camilla Calvieri, Ivano Eberini, Junichi Sadoshima, Adrian J Hobbs, Massimo Volpe, Speranza Rubattu.   

Abstract

RATIONALE: C2238 atrial natriuretic peptide (ANP) minor allele (substitution of thymidine with cytosine in position 2238) associates with increased risk of cardiovascular events.
OBJECTIVE: We investigated the mechanisms underlying the vascular effects of C2238-αANP. METHODS AND
RESULTS: In vitro, human umbilical vein endothelial cell were exposed to either wild-type (T2238)- or mutant (C2238)-αANP. Cell survival and apoptosis were tested by Trypan blue, annexin V, and cleaved caspase-3 assays. C2238-αANP significantly reduced human umbilical vein endothelial cell survival and increased apoptosis. In addition, C2238-αANP reduced endothelial tube formation, as assessed by matrigel. C2238-αANP did not differentially modulate natriuretic peptide receptor (NPR)-A/B activity with respect to T2238-αANP, as evaluated by intracellular cGMP levels. In contrast, C2238-αANP, but not T2238-αANP, markedly reduced intracellular cAMP levels in an NPR-C-dependent manner. Accordingly, C2238-αANP showed higher affinity binding to NPR-C, than T2238-αANP. Either NPR-C inhibition by antisense oligonucleotide or NPR-C gene silencing by small interfering RNA rescued survival and tube formation of human umbilical vein endothelial cell exposed to C2238-αANP. Similar data were obtained in human aortic endothelial cell with NPR-C knockdown. NPR-C activation by C2238-αANP inhibited the protein kinase A/Akt1 pathway and increased reactive oxygen species. Adenovirus-mediated Akt1 reactivation rescued the detrimental effects of C2238-αANP. Overall, these data indicate that C2238-αANP affects endothelial cell integrity through NPR-C-dependent inhibition of the cAMP/protein kinase A/Akt1 pathway and increased reactive oxygen species production. Accordingly, C2238-αANP caused impairment of acetylcholine-dependent vasorelaxation ex vivo, which was rescued by NPR-C pharmacological inhibition. Finally, subjects carrying C2238 minor allele showed early endothelial dysfunction, which highlights the clinical relevance of our results.
CONCLUSIONS: C2238-αANP reduces endothelial cell survival and impairs endothelial function through NPR-C signaling. NPR-C targeting represents a potential strategy to reduce cardiovascular risk in C2238 minor-allele carriers.

Entities:  

Keywords:  Akt; T2238C gene variant; atrial natriuretic peptide; endothelial dysfunction; natriuretic peptide receptor type C

Mesh:

Substances:

Year:  2013        PMID: 23529183     DOI: 10.1161/CIRCRESAHA.113.301325

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  20 in total

Review 1.  Natriuretic peptides in cardiovascular diseases: current use and perspectives.

Authors:  Massimo Volpe; Speranza Rubattu; John Burnett
Journal:  Eur Heart J       Date:  2013-11-13       Impact factor: 29.983

Review 2.  Corin in natriuretic peptide processing and hypertension.

Authors:  Yiqing Zhou; Qingyu Wu
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

Review 3.  Natriuretic Peptides and Cardiometabolic Health.

Authors:  Deepak K Gupta; Thomas J Wang
Journal:  Circ J       Date:  2015-06-23       Impact factor: 2.993

4.  Distinct roles of N-glycosylation at different sites of corin in cell membrane targeting and ectodomain shedding.

Authors:  Hao Wang; Tiantian Zhou; Jianhao Peng; Ping Xu; Ningzheng Dong; Shenghan Chen; Qingyu Wu
Journal:  J Biol Chem       Date:  2014-12-01       Impact factor: 5.157

Review 5.  Atrial natriuretic peptide in cardiovascular biology and disease (NPPA).

Authors:  Wei Song; Hao Wang; Qingyu Wu
Journal:  Gene       Date:  2015-06-12       Impact factor: 3.688

6.  Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study.

Authors:  Valentina Cannone; Brenda K Huntley; Timothy M Olson; Denise M Heublein; Christopher G Scott; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  Hypertension       Date:  2013-09-16       Impact factor: 10.190

7.  Corin mutations K317E and S472G from preeclamptic patients alter zymogen activation and cell surface targeting. [Corrected].

Authors:  Ningzheng Dong; Tiantian Zhou; Yue Zhang; Meng Liu; Hui Li; Xiaoyi Huang; Zhenzhen Liu; Yi Wu; Koichi Fukuda; Jun Qin; Qingyu Wu
Journal:  J Biol Chem       Date:  2014-05-14       Impact factor: 5.157

Review 8.  Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function.

Authors:  Kailash N Pandey
Journal:  Physiol Genomics       Date:  2018-08-31       Impact factor: 3.107

9.  Endothelial C-type natriuretic peptide maintains vascular homeostasis.

Authors:  Amie J Moyes; Rayomand S Khambata; Inmaculada Villar; Kristen J Bubb; Reshma S Baliga; Natalie G Lumsden; Fang Xiao; Paul J Gane; Anne-Sophie Rebstock; Roberta J Worthington; Michela I Simone; Filipa Mota; Fernando Rivilla; Susana Vallejo; Concepción Peiró; Carlos F Sánchez Ferrer; Snezana Djordjevic; Mark J Caulfield; Raymond J MacAllister; David L Selwood; Amrita Ahluwalia; Adrian J Hobbs
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

10.  Atrial natriuretic Peptide single nucleotide polymorphisms in patients with nonfamilial structural atrial fibrillation.

Authors:  Pietro Francia; Agnese Ricotta; Alessandra Frattari; Rosita Stanzione; Anna Modestino; Federico Mercanti; Carmen Adduci; Isabella Sensini; Maria Cotugno; Cristina Balla; Speranza Rubattu; Massimo Volpe
Journal:  Clin Med Insights Cardiol       Date:  2013-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.